Pulmonary Functions Test in Patients After Fontan Operation
Long-term Effects on Pulmonary Function in Post- Fontan Operation
1 other identifier
observational
15
0 countries
N/A
Brief Summary
Developed in the early 1970s, Fontan Operation has provided palliative care for patients with single ventricle physiology. Single ventricle is a rare subclass of the atrioventricular (AV) alignment abnormalities double inlet and common inlet ventricles (and rarely, straddling tricuspid valve), in which there is only one ventricular sinus \[1\]. Most patients present with symptoms of congestion , low cardiac output, and deep cyanosis immedietly after birth. Untreated, these heart anomalies are highly lethal. Neonatal heart transplantation is implacable because of shortage of donors. Fontan operation is a three staged palliative procedure: the single ventricle pumping blood to the systemic circulation , while blood flows laminarly to the lungs through direct anastomosis of the superior and inferior vena cavae (total cavo pulmonary connections), inevitably by-passing the right heart . This procedure has been shown to immediately correct the mixed venous blood dysfunction, providing treatment for the prominent signs of cyanosis. Along with its beneficial outcomes, Fontan circulation patients have been documented to have a variety of post-operative late complications. Of most substantial, increased systemic vascular resistance (mean of 10-15 mmHg higher) \[2\], systolic dysfunction as a result of decreased preload and increase afterload \[3\], and atrial arrhythmias \[4\]. With the advent of bypassing right-heart circulation with Fontan operation, the pulmonary vascular bed is exposed to a new atmosphere of blood flow. Instead of physiological pulsatile flow in normal circulation, the pulmonary vasculature is receiving slow velocity, laminar flow \[5\]. Patients post-Fontan operations have been documented to have restrictive-type pulmonary function, but still yet to be correlated with Fontan circulation or as a possible result of prior lung tissue injury from the pre/intra-operation high volume blood flow. Regardless, Fontan patients are described to have decreased pulmonary function. The purpose of this research effort is to document and analyze the pulmonary function of those patients post-Fontan operation. It is still unclear as to what the long-term effects of Fontan operation are towards the pulmonary vascular bed, leaving us questions about the effects on lung capacities, ventilation-perfusion efficiency, and oxygen saturation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2011
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2011
CompletedFirst Posted
Study publicly available on registry
August 10, 2011
CompletedStudy Start
First participant enrolled
September 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedAugust 10, 2011
August 1, 2011
6 months
August 9, 2011
August 9, 2011
Conditions
Keywords
Eligibility Criteria
A total number of 15 Fontan patients , aged 10 years and older , with 1-2 NYHA class functional capacity. All will have total pulmonary function tests according to recognized pulmonary protocols. Results will be normalized to age-dependent pulmonogram. Exclusion criteria includes patients with acute pulmonary illness. Generation of Data: 1. Spirometry-Spirometry will be performed in accordance with ATS/ERS (American Thoracic Society/ European Respiratory Society) Task Force 2. Whole Body Plethysmography- FRCpleth will be measured 3. MCT - Methacholine challenge tests will be performed 4. FENO: Measurement of FENO will be performed by portable electrochemical analyzer NIOX MINO (Aerocrine AB, Smidesvägen, Sweden),\[10\] and according to ATS recommendations .
You may qualify if:
- Fontan patient NYHA 1-2
- Age - 10-99
You may not qualify if:
- Pregnant woman
- Acute pulmonary disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- PRINCIPAL INVESTIGATOR
Asaad khoury, MD
Rambam Health Care Campus
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 9, 2011
First Posted
August 10, 2011
Study Start
September 1, 2011
Primary Completion
March 1, 2012
Study Completion
September 1, 2012
Last Updated
August 10, 2011
Record last verified: 2011-08